Clinical Trials Logo

Advanced Cancers clinical trials

View clinical trials related to Advanced Cancers.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT02873975 Completed - Advanced Cancers Clinical Trials

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Start date: October 12, 2016
Phase: Phase 2
Study type: Interventional

This research study is studying a checkpoint kinase 1 (CHK1) inhibitor as a possible treatment for advanced solid tumors that harbor genetic alterations in the homologous repair (HR) pathway, genetic alterations that indicate replication stress, or with CCNE1 amplification.

NCT ID: NCT02801045 Completed - Clinical trials for Psychological Stress

Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient

Start date: October 20, 2016
Phase: N/A
Study type: Interventional

This study evaluates from the patient's perspective which elements of the own artistic creative process are the source of a beneficial change for him/her and how those elements influence in their end of life experience.

NCT ID: NCT02597478 Completed - Advanced Cancers Clinical Trials

Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

Start date: January 4, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical research study is to learn if fentanyl can help shortness of breath in cancer patients. Researchers also want to learn if the study drug can help to improve your physical function.

NCT ID: NCT02571036 Completed - Clinical trials for Gastrointestinal Stromal Tumors

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Start date: November 2015
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.

NCT ID: NCT02561234 Completed - Advanced Cancers Clinical Trials

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

Start date: October 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is the first-in-human study of the safety of increasing dose levels of AEB1102 in patients with advanced cancers. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and tumor growth.

NCT ID: NCT02558257 Completed - Advanced Cancers Clinical Trials

Perception of Palliative Care Encounter

Start date: August 16, 2015
Phase:
Study type: Observational

Objectives: Primary Objective The primary objective is to determine patients' perceptions of the timeliness of their referral to an outpatient palliative care clinic. The secondary objectives are to determine: 1. The factors and variables associated with perception of timeliness such as age, gender, and symptom distress 2. The patients' perceptions of the physical environment of the outpatient clinic at UT MD Anderson Cancer Center (UTMDACC) such as lighting, music, and lack of a waiting room; and 3. If there is an association between level of distress (physical, psychological, and spiritual distress as measured by Edmonton Symptom Assessment Scale (ESAS) and the usefulness of the referral to palliative care center.

NCT ID: NCT02523378 Completed - Advanced Cancers Clinical Trials

Edmonton Symptom Assessment Scale: Self-Completion vs. Assisted-Completion

Start date: August 13, 2015
Phase: N/A
Study type: Interventional

The goal of this research study is to learn how easy participants think it is to complete a symptom questionnaire.

NCT ID: NCT02508662 Completed - Solid Tumors Clinical Trials

Registry Study for Personalized Cancer Therapy

Start date: July 21, 2015
Phase:
Study type: Observational

Objectives: Primary Objectives: To evaluate the anti-cancer activity of commercially available, targeted anti-cancer therapies used off-label for treatment in patients with advanced solid cancer with known genomic aberrations. Secondary Objectives: To determine outcomes of patients who were treated with matched targeted anti-cancer therapies based on known genomic aberrations. To obtain treatment related adverse events in patients with advanced solid tumor who were treated with off -label targeted therapies. To determine co-genomic aberrations that may contribute to treatment response or resistance mechanisms. To determine feasibility of detecting the genomic alterations in plasma, and the genomic evolution of circulating biomarkers.

NCT ID: NCT02498899 Completed - Advanced Cancers Clinical Trials

Message 2: The Effect of Message Content and Clinical Outcome on Patient's Perception of Physician Compassion

Start date: July 2015
Phase: N/A
Study type: Interventional

The goal of this research study is to learn how patients view their doctor's compassion about supportive care and treatment options for advanced cancer patients.

NCT ID: NCT02459964 Completed - Pain Clinical Trials

Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain

Start date: September 14, 2015
Phase: Phase 4
Study type: Interventional

The goal of this clinical research study is to compare fentanyl nasal spray with a standard drug given by vein (hydromorphone hydrochloride) to help reduce pain related to cancer in patients coming to the emergency department.